{"url_path":"/sec/onco/8-k/2026-05-14/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1782107/0001213900-26-056109-index.html","accession_number":"0001213900-26-056109","cik":"0001782107","ticker":"ONCO","issuer_name":"Onconetix, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1782107/0001213900-26-056109-index.html","primary_entity_key":"0001782107","primary_entity_name":"Onconetix, Inc."},"word_count":107,"has_tables":true,"body_markdown":"**Item 8.01 Other Events.**\n\n \n\nOn\nMay 13, 2026, Onconetix, Inc. issued a press release on the first quarter operational and clinical progress of its fully-owned Swiss subsidiary,\nProteomedix AG, a developer of Proclarix®, a diagnostic blood test used in combination with prostate-specific antigen to identify\nclinically significant prostate cancer. The press release details, among other things, two recently published peer-reviewed papers on\nthe performance and prognostic value of Proclarix, as well as the initiation of a multi-center clinical study with Labcorp Holdings Inc.\nin the U.S. to evaluate Proclarix.\n\n \n\nA\ncopy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K."}